Peru: These 18 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Peru
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Peru: These 18 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Peru Patent 20,060,215
Patent Title: 4-FENILAMINO-QUINAZOLIN-6-IL-AMIDAS
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety-three patent family members in forty-eight countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?
Generic name: indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Peru Patent 20,060,098
Patent Title: DISPOSITIVO INHALADOR
ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.
This drug has eighty-six patent family members in thirty-nine countries.
See drug price trends for ARCAPTA NEOHALER.
The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.
When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?
Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Peru Patent 20,060,098
Patent Title: DISPOSITIVO INHALADOR
UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.
This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON
See drug price trends for UTIBRON.
The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.
When can VITEKTA (elvitegravir) generic drug versions launch?
Generic name: elvitegravir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Peru Patent 20,060,358
Patent Title: CRISTAL ESTABLE DEL COMPUESTO 4-OXOQUINOLINA
VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.
This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA
The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.
When can VITEKTA (elvitegravir) generic drug versions launch?
Generic name: elvitegravir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Peru Patent 20,120,361
Patent Title: COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN FORMAS CRISTALINAS DE ACIDO 6-(3-CLORO-2-FLUOROBENCIL)-1-[(S)-1-HIDROXIMETIL-2-METILPROPIL]-7-METOXI-4-OXO-1, 4-DIHIDROQUINOLINA-3-CARBOXILICO
VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.
This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA
The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Peru Patent 20,060,425
Patent Title: FORMULACION DE TABLETA REVESTIDA QUE COMPRENDE SAXAGLIPTINA
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Peru Patent 20,060,425
Patent Title: FORMULACION DE TABLETA REVESTIDA QUE COMPRENDE SAXAGLIPTINA
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can NUCYNTA (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: Peru Patent 20,060,372
Patent Title: FORMA CRISTALINA DE CLORHIDRATO DE (-)-(1R, 2R)-3-(3-DIMETILAMINO-1-ETIL-2-METILPROPIL)-FENOL
NUCYNTA is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.
This drug has forty-five patent family members in twenty-six countries. There has been litigation on patents covering NUCYNTA
See drug price trends for NUCYNTA.
The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can NUCYNTA ER (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: Peru Patent 20,060,372
Patent Title: FORMA CRISTALINA DE CLORHIDRATO DE (-)-(1R, 2R)-3-(3-DIMETILAMINO-1-ETIL-2-METILPROPIL)-FENOL
NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and seventy-two patent family members in thirty-one countries. There has been litigation on patents covering NUCYNTA ER
See drug price trends for NUCYNTA ER.
The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can YONDELIS (trabectedin) generic drug versions launch?
Generic name: trabectedin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Peru Patent 20,060,925
Patent Title: COMPOSICION FARMACEUTICA QUE COMPRENDE ECTEINASCIDINA Y UN DISACARIDO
YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS
See drug price trends for YONDELIS.
The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.
When can YONDELIS (trabectedin) generic drug versions launch?
Generic name: trabectedin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Peru Patent 20,100,089
Patent Title: COMPOSICION FARMACEUTICA QUE COMPRENDE ECTEINASCIDINA Y UN DISACARIDO
YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS
See drug price trends for YONDELIS.
The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.
When can KUVAN (sapropterin dihydrochloride) generic drug versions launch?
Generic name: sapropterin dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2024
Generic Entry Controlled by: Peru Patent 20,061,294
Patent Title: FORMULACION DE TABLETA ESTABLE QUE CONTIENE POLIMORFO B DE (6R)-L-ERITRO-TETRA HIDROBIOPTERINA
KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.
This drug has one hundred and seventeen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN
See drug price trends for KUVAN.
The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.
When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?
Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Peru Patent 20,061,148
Patent Title: SAL POTASICA DE N-(4-FLUOROBENCIL)-5-HIDROXI-1-METIL-2-(1-METIL-1-{[(5-METIL-1,3,4-OXADIAZOL-2-IL)CARBONIL]AMINO}ETIL)-6-OXO-1,6-DIHIDROPIRIMIDIN-4-CARBOXAMIDA
DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.
This drug has ninety-five patent family members in forty-three countries.
The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.
When can ISENTRESS (raltegravir potassium) generic drug versions launch?
Generic name: raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Peru Patent 20,061,148
Patent Title: SAL POTASICA DE N-(4-FLUOROBENCIL)-5-HIDROXI-1-METIL-2-(1-METIL-1-{[(5-METIL-1,3,4-OXADIAZOL-2-IL)CARBONIL]AMINO}ETIL)-6-OXO-1,6-DIHIDROPIRIMIDIN-4-CARBOXAMIDA
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and twenty-five patent family members in forty-five countries.
See drug price trends for ISENTRESS.
The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.
When can CORLANOR (ivabradine) generic drug versions launch?
Generic name: ivabradine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Peru Patent 20,061,142
Patent Title: FORMA CRISTALINA GAMMA DE CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.
When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?
Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Peru Patent 20,061,009
Patent Title: FORMA CRISTALINA BETA DE CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACION, Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.
When can NEXAVAR (sorafenib tosylate) generic drug versions launch?
Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: Peru Patent 20,061,345
Patent Title: COMPOSICION FARMACEUTICA QUE COMPRENDE SORAFENIB
NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR
See drug price trends for NEXAVAR.
The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.
When can TYKERB (lapatinib ditosylate) generic drug versions launch?
Generic name: lapatinib ditosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 19, 2025
Generic Entry Controlled by: Peru Patent 20,061,430
Patent Title: COMPOSICION FARMACEUTICA QUE COMPRENDE COMPUESTOS DE 4-QUINAZOLINAMINAS
TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in twenty-six countries.
See drug price trends for TYKERB.
The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.
When can VICTRELIS (boceprevir) generic drug versions launch?
Generic name: boceprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 02, 2025
Generic Entry Controlled by: Peru Patent 20,070,011
Patent Title: FORMULACIONES FARMACEUTICAS DE COMPUESTOS INHIBIDORES DE PROTEASA DEL VHC O CATEPSINA
VICTRELIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.
This drug has one hundred and ten patent family members in thirty-three countries.
The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.
When can BOSULIF (bosutinib monohydrate) generic drug versions launch?
Generic name: bosutinib monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 01, 2025
Generic Entry Controlled by: Peru Patent 20,070,190
Patent Title: FORMAS CRISTALINAS DE 4-[(2,4-DICLORO-5-METOXIFENIL)AMINO]-6-METOXI-7-[3-(4-METIL-1-PIPERAZINIL)PROPOXI]-3-QUINOLINCARBONITRILO Y METODOS DE PREPARACION DE LAS MISMAS
BOSULIF is a drug marketed by Pf Prism Cv. There are five patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF
See drug price trends for BOSULIF.
The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.